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Abstract
Background: Sarcopenia often co-exists with obesity, and may have additive effects on insulin resistance. Sarcopenic obese
individuals could be at increased risk for type 2 diabetes. We performed a study to determine whether sarcopenia is
associated with impairment in insulin sensitivity and glucose homeostasis in obese and non-obese individuals.
Methodology: We performed a cross-sectional analysis of National Health and Nutrition Examination Survey III data utilizing
subjects of 20 years or older, non-pregnant (N=14,528). Sarcopenia was identified from bioelectrical impedance
measurement of muscle mass. Obesity was identified from body mass index. Outcomes were homeostasis model
assessment of insulin resistance (HOMA IR), glycosylated hemoglobin level (HbA1C), and prevalence of pre-diabetes (6.0#
HbA1C,6.5 and not on medication) and type 2 diabetes. Covariates in multiple regression were age, educational level,
ethnicity and sex.
Principal Findings: Sarcopenia was associated with insulin resistance in non-obese (HOMA IR ratio 1.39, 95% confidence
interval (CI) 1.26 to 1.52) and obese individuals (HOMA-IR ratio 1.16, 95% CI 1.12 to 1.18). Sarcopenia was associated with
dysglycemia in obese individuals (HbA1C ratio 1.021, 95% CI 1.011 to 1.043) but not in non-obese individuals. Associations
were stronger in those under 60 years of age. We acknowledge that the cross-sectional study design limits our ability to
draw causal inferences.
Conclusions: Sarcopenia, independent of obesity, is associated with adverse glucose metabolism, and the association is
strongest in individuals under 60 years of age, which suggests that low muscle mass may be an early predictor of diabetes
susceptibility. Given the increasing prevalence of obesity, further research is urgently needed to develop interventions to
prevent sarcopenic obesity and its metabolic consequences.
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Introduction
Obesity and type 2 diabetes constitute a significant health care
concern in the United States and other developing and developed
nations, especially since their incidence is on the rise in children
and young adults. Sarcopenic obesity, the co-existence of
sarcopenia and obesity, [1] is seen in 5–10% of healthy,
ambulatory, community-dwelling Americans in their sixties, rising
to over 50% in those over age eighty [2]. Studies indicate that up
to 50% of muscle may be lost by the age of 90 years[3]. Since
muscle is the primary tissue contributing to whole-body insulin-
mediated glucose disposal, sarcopenia may be an important causal
factor in age-induced insulin resistance and type 2 diabetes
susceptibility.
Inflammation is a central underpinning in the pathogenesis of
insulin resistance and is also seen in both obesity and sarcopenia.
Inflammation may be an important mediator in restraining
myogenesis and/or accelerating muscle protein degradation. In
addition, intramyocellular lipid accumulation, seen in obesity,
results in the formation of bioactive lipid intermediates and lipid
peroxides, which are known to activate pro-inflammatory
cascades [4]. Furthermore, myokines secreted by skeletal muscle
[5] have been found to prevent inflammation and insulin
resistance, thus counteracting the pro-inflammatory and meta-
bolic effects of adipokines produced in adipose tissue; the relative
paucity of myokines relative to adipokines in sarcopenic obesity
may increase the risk of metabolic and cardiovascular disease
[6].
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10805Recent studies in rodents suggest a strong inverse association
between muscle mass and disease risk. Even a modest increase in
muscle mass can prevent diet-induced obesity and insulin
resistance as well as atherogenesis in prone mice[5,7]. Consistent
with this, Stephen et al. found a positive association between
sarcopenic obesity and cardiovascular disease in the older adults
from the Cardiovascular Health Study [8]. However, since type II
muscle fibers, described as glycolytic and insulin resistant [9], are
lost to a greater extent than type I fibers [10] in age-related muscle
atrophy, sarcopenia could theoretically also increase insulin
sensitivity and cause some beneficial alterations in glucose
metabolism in older adults [11].
Accordingly, we hypothesize that sarcopenic obese individuals
have more insulin resistance and higher prevalence of dysglycemia
(i.e., impaired glucose tolerance and diabetes), than individuals
with neither sarcopenia nor obesity, those with obesity alone
(without sarcopenia), and those with sarcopenia alone (without
obesity). We further hypothesize that this association will be
stronger in young and middle aged adults than in older adults, in
whom sarcopenia may mean a preferential reduction in insulin-
resistant fibers.
To test this hypothesis, we assessed the level of insulin resistance
and dysglycemia in sarcopenic obese individuals, obese individuals
without sarcopenia, sarcopenic individuals without obesity, and in
those with neither sarcopenia nor obesity, in a nationally
representative sample, and tested for effect modification by age.
Methods
Ethics statement
Written informed consent was obtained from all participants,
and the protocol was approved by the institutional review board of
the National Center for Health Statistics, and the study procedures
were carried out in accordance with the principles of the
Declaration of Helsinki.
Design and Methods
The National Health and Nutrition Examination Survey
(NHANES) III was a national survey conducted from 1988
through 1994, using a stratified, multistage, probability cluster
design. The total sample included 33,199 persons[12] of whom,
17,756 were older than 20 years and non-pregnant. The full
evaluation included a standardized home interview (with a
medication review), a physical examination in a mobile examina-
tion center, and a fasting blood draw.
Our analytic sample (N=14,528) was restricted to those who
were 20 years or older and non-pregnant, and had measurements
of bioelectrical impedance (BI), height, and body weight, the three
variables we utilized to indirectly estimate the presence of
sarcopenic obesity. Participants who had cardiac pacemakers or
had previously undergone limb amputation were excluded from
the measurement of BI [13].The analytic sample included 2370
women and 2284 men who were 60 years of age or older.
Measurements: Exposures
Body height and weight were measured, and converted to body
mass index (BMI) in units of kg/meter-squared. Obesity was
defined as BMI .30 kg/m
2. Waist size and hip size were
measured by standard protocols and waist-to-hip circumference
ratio was created. BI was measured using the Valhalla Scientific
Body Composition Analyzer 1990 B [14], and used to estimate
skeletal muscle mass (in kg) via the BI analysis equation of Janssen
et al [15].
Skeletal muscle mass~
0:401| height2
BI

z 3:825|sex ðÞ z 0:071|age ðÞ

z5:102
with height measured in cm, BI measured in ohms, sex coded 1 for
men and 0 for women, and age measured in years. Muscle mass (in
kg) was divided by body mass (in kg) and multiplied by 100% to
create skeletal muscle index (SMI). Similar to the approach used to
Table 1. Descriptive statistics (median with inter-quartile range, or percentage).
Study Sample
Complete sample(N=14,528) Under 60 years(N=9,892) 60 years or older(N=4,636) Excluded *(N=3,228)
Age (years) 45.0(32.0 to 64.0) 37.0 (29.0 to 45.0) 71.0 (65.0 to 78.0) 66.0 (41.0 to 80.0)
Body mass index (kg/m
2) 26.3(23.2 to 30.0) 26.2 (23.0 to 30.2) 26.5 (23.6 to 29.8) 26.3 (22.6 to 30.4)
Skeletal muscle index (%) 33.9 (27.9 to 39.4) 35.0 (29.2 to 40.5) 31.0 (25.8 to 36.9) -
Glycosylated hemoglobin (%) 5.40 (5.00 to 5.7)(n=14026) 5.20 (4.90 to 5.60)(n=9537) 5.60 (5.30 to 6.10)(n=4489) 5.50 (5.10 to 5.90)(n=1622)
HOMA-IR (mg/dl 6mU/ml) 2.12 (1.45 to 3.30)(n=12046) 2.00 (1.38 to 3.10)(n=8173 ) 2.38 (1.61 to 3.67)(n=3873) 2.25 (1.46 to 3.46)(n=1031)
Gender: Male 48.3% 47.9% 49.2% 50.3%
NH White 42.2% 34.6% 58.2% 51.2%
NH Black 27.3% 31.0% 19.6% 24.9%
Hispanic 26.4% 29.8% 19.0% 21.8%
Other 4.18% 4.60% 3.28% 2.23%
Sarcopenic without obesity 1.14% 0.18% 3.17% -
Obese without sarcopenia 21.0% 22.9% 17.1% -
Sarcopenic obesity 4.50% 3.39% 6.9% -
Pre-diabetes 25.6% 20.6% 35.8% 22.9%
Diabetes 13.9% 8.7% 24.4% 35.0%
*Those in the NHANES III sample who were older than 20 years and not pregnant, but were excluded because they were missing bioelectrical impedance or body mass
index measurement.
doi:10.1371/journal.pone.0010805.t001
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defined as SMI more than two standard deviations below the sex-
specific, young adult (ages, 18-39) means: 31.0% in men and
22.0% in women [17].
Measurements: Outcomes
Serum insulin and plasma glucose were measured from fasting
blood samples (if fasted 6 hours or more) using radioimmunoassay
and a hexokinase enzymatic method, respectively [13], and used to
calculate insulin resistance by the Homeostasis model assessment
of insulin resistance (HOMA-IR) which is approximated using the
formula below:
HOMA-IR ~ fasting glucose | fasting insulin=22:5
with glucose in mmol/L and insulin in mU/ml, for participants
whose fasting plasma glucose ranged from 3.0 to 25.0 mmol/l and
fasting insulin ranged from 3 to 55 mU/ml[18]. HOMA-IR data
were available for 12,046 subjects. Glycosylated hemoglobin
(HbA1c) was measured using an ion-exchange high-performance
liquid chromatography method using the Diamat Analyzer
System, and used to define dysglycemia based on standard HbA1C
thresholds [19]. Specifically, diabetes (DM) was defined as one or
more of 1) HbA1C $6.5% 2) Fasting glucose $7 mmol/L
(126 mg/dl), 3) self report of DM and /or 4) use of DM
medication (oral hypoglycemic agents and /or insulin), and pre-
diabetes was defined by 1) HbA1C $6% but ,6.5% OR fasting
$5.5 mmol/L(100 mg/dL) but ,7.0 mmol/L(126 mg/dL), 2) no
self-reported DM, and 3) absence of DM medications.
Measurements: Covariates
Age, race/ethnicity (non-Hispanic white, non-Hispanic black,
Mexican American, and other), and completed years of education
and sex were obtained from self reports. Serum C-reactive protein
(CRP) concentration was measured using latex-enhanced nephe-
lometry with a Behring Nephelometer Analyzer System (Behring
Diagnostics Inc)[20]. Details about the laboratory procedures and
quality control have been published [20]. Serum CRP levels
greater than 10 mg/dL were set to missing to avoid capturing
acute elevations in CRP due to infectious causes.
Statistical Analyses
To study the association between sarcopenic obesity and insulin
resistance/dysglycemia, we examined four outcomes (HOMA-IR,
HbA1C, prevalence of pre-diabetes, prevalence of diabetes
mellitus) in sarcopenic obese individuals, sarcopenic non-obese
individuals, obese non-sarcopenic individuals, and those with
neither sarcopenia nor obesity (the reference group). To control
for confounders (namely age, sex, education, and race/ethnicity),
we used multivariable logistic regression for the two prevalence
outcomes (diabetes and pre-diabetes) and multivariable linear
regression for the continuous outcomes: HbA1C and HOMA-IR;
these variables were log-transformed before model fitting. To
minimize residual confounding by age, we included age both as a
continuous and a categorical variable (20–29 y, 30–39 y, 40–49 y,
50–59 y, 60–74 y, and $75 y). We similarly, included years of
education both as a continuous and a categorical variable (,12 y,
12–14 y, 15–17 y, and .17 y, intended to capture the effect of
credentialing at high school and college). We also repeated the
analyses after excluding diabetics to minimize confounding by
reverse causation (i.e., diabetes leading to sarcopenia and/or
obesity).
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years vs. .=60 years) and gender by including interaction terms
in the models for each of the four dependent variables. Based on
the results of the interaction testing, we conducted further stratified
analyses. In supplementary analyses, to test if sarcopenia/obesity
associations with inflammation are consistent with their dysglyce-
mia associations, we also examined serum CRP level (after log-
transformation) as a continuous outcome in multivariable linear
regression.
We used SAS, release 9.2 (SAS Institute Inc, Cary, NC) for all
the analyses.
Results
The study sample was representative of the complete NHANES
sample that was non pregnant and 20 years or older (Table 1),
except that the study participants were younger, less frequently
male, non-Hispanic White, and diabetic than those excluded from
the study. Those excluded had similar BMI, HOMA-IR, and
HbA1C as those in the study sample. The average age of
participants in the study sample was 45 years, 51.7% were female
and 42.2% were non-Hispanic Whites.
Sarcopenia was more prevalent in obese than non-obese
participants (4.5% vs. 1.14%), and this was true both in those
under 60 years of age (3.4% vs. 0.2%) and in those 60 years and
older (6.9% vs. 3.2%). Comparing participants under 60 years of
age with those 60 years or older in the study sample, the older
group had lower SMI and more sarcopenia without obesity but
less obesity without sarcopenia. Yet, the older adults had more
insulin resistance and dysglycemia than the younger group:
Median HbA1C, HOMA IR, and prevalence of pre-diabetes
and DM were all higher in older adults.
In the complete sample, adjusted for age, sex, educational level
(both as a continuous and categorical variable) and race/ethnicity,
sarcopenia (without obesity) was significantly associated with
increased HOMA-IR and pre-diabetes, but not with dysglycemia
or diabetes outcomes, and in particular there was a marginally
significant association with decreased risk of DM (Table 2). In
contrast, obesity with and without sarcopenia was associated
positively with all four outcomes. However, consistent with our
main hypothesis, participants with sarcopenic obesity had
significantly higher index of insulin resistance (HOMA-IR ratio
1.16, 95% CI 1.12 to 1.18, p,0.001) and chronic hyperglycemia
(HbA1C ratio 1.021, 95%% CI 1.011 to 1.043, p=0.002) than
obese, non-sarcopenic participants, but they did not have higher
prevalence of pre-diabetes and DM. This pattern of associations
was essentially unchanged when diabetics were excluded to reduce
confounding by reverse causation (i.e. diabetes leading to
sarcopenia or obesity) - See Table 2.
In interaction testing, age (dichotomized at 60 years) modified
effects of sarcopenia and obesity (Table 3). All interactions
between gender and sarcopenia/obesity were non significant at
the 0.1 level (data not shown).
In age-stratified analyses, associations with insulin resistance
and dysglycemia were stronger in the younger group (See Tables 4
and 5). In those under 60 years of age, sarcopenia without obesity
was associated with higher HOMA-IR and HbA1C, but not with
pre-diabetes and DM prevalence (see Table 4). However, the odds
ratio confidence intervals for the latter two outcomes were
unusually wide, which may reflect reduced power due to the
small number of sarcopenic non-obese participants in the younger
age group. In comparison to obese, non-sarcopenic participants,
younger participants with sarcopenic obesity had significantly
higher HOMA-IR (HOMA-IR (ratio 1.26, 95% CI 1.22 to 1.31,
p=,.0001), higher HbA1C (ratio 1.054, 95% CI 1.032 to 1.062,
p ,.0001), and higher prevalence of DM (odds ratio 1.54, 95% CI
1.44 to 1.65, p=,.0001).
In contrast, in those 60 years and older, sarcopenia without
obesity was associated with higher HOMA-IR and higher
prevalence of pre-diabetes but not with HbA1c or prevalence of
DM (see Table 5). Moreover, although sarcopenic obesity
(compared to the non-sarcopenic, non-obese referent) was
significantly associated with HOMA-IR, HBA1C, and DM
outcomes, older sarcopenic obese individuals did not significantly
differ in any of the outcomes from older obese, non-sarcopenic
individuals.
To determine whether sarcopenia/obesity associations with
inflammation in the two age groups are in concordance with their
associations with insulin resistance and dysglycemia, we examined
log CRP as outcome in parallel linear regression models. In those
under 60 years of age, sarcopenia was independently associated
with increased CRP in both non-obese (CRP ratio 1.13, 95% CI
1.01 to 1.30, p=0.02) and obese individuals (CRP ratio 1.093,
95% CI 1.041 to 1.143, p=0.002). In those 60 years or older,
sarcopenia was not independently associated with increased CRP
in either obese individuals (CRP ratio 1.052, 95% CI 0.991 to
1.111, p=0.1) or in non-obese older adults (CRP ratio 1.00, 95%
CI 0.92 to 1.08, p=0.99), mirroring the pattern of sarcopenia
associations with pre-diabetes and diabetes.
Table 3. P values for interactions of age (,60 years vs. $60 years) with sarcopenia, obesity, and sarcopenic obesity in models
adjusted for age, sex, race, and education.
Outcomes:Effect size:
Insulin
resistanceHOMA-IR ratio
1
Glycosylated hemoglobin
HbA1C ratio
2
Pre-diabetes
Odds Ratio
3
Diabetes
Odds Ratio
Sarcopenia without obesity 0.13 0.01 0.4 0.07
Obesity without sarcopenia ,.0001 0.3 0.003 0.04
Sarcopenic Obesity ,.0001 ,.0001 0.04 0.0005
Sarcopenia without obesity - diabetics excluded 0.2 0.3
Obesity without sarcopenia - diabetics excluded ,.0001 0.6
Sarcopenic Obesity diabetics excluded ,.0001 ,.0001
1Ratio of HOMA IR in sarcopenic obese group to HOMA IR in reference group (neither sarcopenic nor obese) where HOMA IR is the Homeostatic Model Assessmento f
Insulin Resistance.
2Ratio of HbA1C in sarcopenic obese group to HbA1C in reference group (neither sarcopenic nor obese) where HbA1C is the blood level of glycosylated hemoglobin.
3Pre-diabetes is defined as a 1) HbA1C $6 but ,6.5%, OR fasting glucose $5.5 but ,7 mmol/L, 2)no self-reported DM, and 3) absence of DM medications.
doi:10.1371/journal.pone.0010805.t003
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As hypothesized, sarcopenic obesity was strongly associated with
increased insulin resistance and dysglycemia. In addition,
sarcopenia was associated with increased insulin resistance in
both non-obese and obese individuals, and also associated with
higher levels of HbA1C in obese individuals. Thus, sarcopenic
obese individuals had significantly higher HOMA-IR and HbA1C
levels than obese individuals without sarcopenia, confirming our
hypothesis that the combination of sarcopenia and obesity leads to
more severe insulin resistance and dysglycemia.
However, there were important differences in the effect of
combined sarcopenia and obesity, by age. In those under 60 years
of age, sarcopenia was strongly associated with more insulin
resistance and higher HbA1C levels in both non-obese and obese
individuals, and also associated with higher prevalence of diabetes
in obese individuals. Thus, the younger sarcopenic obese
individuals had significantly and markedly higher HOMA-IR
and HbA1C levels and diabetes prevalence than younger obese
individuals without sarcopenia. On the other hand, in those 60
years or older, although sarcopenia was associated with increased
insulin resistance in both non-obese and obese individuals,
sarcopenia did not add to the risk of insulin resistance or
dysglycemia in obese older adults.
This marked age difference in the metabolic effect of sarcopenia
is likely to be the result of differences in the etiology of sarcopenia
in young compared with old individuals. While sarcopenia in
young and middle-aged adults likely reflects reduced accumulation
of skeletal muscle mass over the life course, in older individuals
sarcopenia results from a combination of inadequate muscle mass
accumulation when younger and reduction in muscle mass from
peak levels when older. Skeletal muscle is a primary tissue
responsible for insulin-mediated glucose disposal; thus in sarcope-
nia, the lower total mass of muscle should cause diminished
insulin-mediated glucose disposal, independent of obesity. How-
ever, type II muscle fibers, which are less responsive to the
metabolic actions of insulin [21], are lost to a greater extent than
type I fibers in age-related muscle atrophy [10]. Thus sarcopenia
due to age-related muscle atrophy could mean increased insulin
sensitivity and more efficient glucose disposal [11]. This might
explain the observed lack of association between sarcopenia and
diabetes in non-obese older adults. However, decrease in type II
muscle fibers has not been shown to improve overall myocellular
insulin action in post-menopausal women [11] and to the contrary,
recent reports show that increased type II fiber population
improves glucose disposal in mice [7]. The role of fiber type
distribution in age-induced insulin resistance remains controver-
sial. In obese older adults however, there is greater lipid content
within skeletal muscle [22], which is associated with diminished
muscle insulin sensitivity [23]; this might in part, explain why
sarcopenia did not confer protection from dysglycemia and
diabetes in obese older adults (unlike in non-obese older adults).
Further work is needed to illuminate the roles of fiber type
distribution and intramyocellular lipid accumulation in age-related
insulin resistance and diabetes.
Chronic low-grade inflammation is now recognized as a central
mediator of obesity-associated insulin resistance [24]. Genetic and
pharmacologic inhibition of inflammatory mediators is shown to
prevent diet- and obesity-induced insulin resistance as well as
prevent accelerated loss of muscle mass with age [25]. Our data
also suggest that in young and middle-aged individuals (both obese
and non-obese) sarcopenia is associated with greater inflammation
(higher levels of serum CRP). This association was not seen in non-
obese older adults. This pattern mirrors the strong association of
sarcopenia with insulin resistance and dysglycemia in young
adults, in contrast to the weaker association in older adults,
suggesting that inflammation may have a role in the development
of metabolic complications from sarcopenia.
Our study had some important limitations. The cross-sectional
nature of the study limits our ability to draw causal inferences from
the relationships observed. For instance, it is possible that diabetes
and dysglycemia lead to sarcopenia and sarcopenic obesity.
However, the strength of the observed associations and their
persistence after exclusion of individuals with type 2 diabetes,
bolster the case for sarcopenia and sarcopenic obesity causing
insulin resistance and dysglycemia. Secondly, as NHANES III was
conducted among the non-institutionalized U.S. population, and
because participants who were physically unable to attend the
mobile examination center were not included in our analysis, we
may have underestimated the prevalence of sarcopenia. Finally,
we used BI to estimate muscle mass, which may have led to some
individuals being erroneously classified in or out of the sarcopenic
obese category. However, such misclassification errors would only
have weakened associations between sarcopenic obesity and
insulin resistance or dysglycemia.
In conclusion, this large national study found that sarcopenic
obesity, to a greater extent than sarcopenia or obesity alone, is
strongly associated with insulin resistance in both young and old
adults, underscoring the important role of low muscle mass as an
independent risk factor for metabolic disease. In those under 60
years of age, sarcopenia also increased the risk of dysglycemia, in
both non-obese and obese individuals. In young as well as in old
adults, sarcopenia was also much more prevalent in obese than in
non-obese individuals. With the ongoing obesity epidemic in the
U.S. and the disturbing increases in the incidence of obesity in
children and young adults, our data suggest that we can expect to
see sharp increases in sarcopenia and diabetes in the coming years.
In this environment, interventions aimed at increasing muscle
mass in younger ages and preventing loss of muscle mass in older
ages may have the potential to reduce type 2 diabetes risk. Further
research is required to understand the pathophysiology and
metabolic basis of the associations documented here, as well as to
develop effective means of preventing sarcopenic obesity and its
metabolic consequences.
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